Huahai Pharmaceutical Co., Ltd. (SHA: 600521) 2025 Annual Profit Distribution: Cash Dividend of RMB 0.1 per Share

Gelonghui, June 11 — Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced its 2025 annual profit distribution implementation notice. The company will distribute a cash dividend of RMB 0.1 per share (inclusive of tax) to all shareholders, based on the total number of shares outstanding as of the equity registration date for this distribution, excluding shares held in the company’s repurchase special securities account (i.e., 1,490,228,596 shares). The equity registration date for this distribution is June 17, 2026, and the ex-dividend date is June 18, 2026.

Gelonghui FinanceJun 11 18:21

Huahai Pharmaceutical (SHA: 600521): Ailamode Tablets received a drug registration certificate

Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced that the company recently received a Drug Registration Certificate for iguratimod tablets, issued by the National Medical Products Administration. The drug is indicated for the treatment of active rheumatoid arthritis and has been approved as a Class 4 chemical drug, which is deemed equivalent to having passed the consistency evaluation. This approval further enriches the company's product portfolio and enhances the market competitiveness of its products.

Zhitong FinanceJun 8 18:04

Huahai Pharmaceutical Co., Ltd. (SHA: 600521): A subsidiary has obtained approval to conduct clinical trials for a drug.

Gelonghui, June 2 — Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced that its subsidiaries, Shanghai Huaaote Biopharmaceutical Co., Ltd. and Huabo Biomedical Technology (Shanghai) Co., Ltd., have recently received a "Notice of Approval for Drug Clinical Trial" from the National Medical Products Administration (NMPA) for a new indication of the HB0056 injection. Drug name: HB0056 injection; Indication: Idiopathic Pulmonary Fibrosis. The development of pharmaceutical products, including clinical trials and the process from regulatory submission to commercial-scale production, involves a lengthy timeline and numerous stages, and is subject to various uncertainties related to technology, regulatory review, and other factors.

Gelonghui FinanceJun 2 18:24

Huahai Pharmaceutical (600521.SH): Brexpiprazole Tablets and Isavuconazonium Sulfate for Injection Received Drug Registration Certificates

Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced that the company recently received Drug Registration Certificates from the National Medical Products Administration (NMPA) for Brexpiprazole Tablets and Isavuconazonium Sulfate for Injection. Under relevant national policies, the approval of these two products as Class 4 chemical drugs is deemed equivalent to passing the consistency evaluation. The approval of these products further diversifies the company's product portfolio and enhances the market competitiveness of its offerings.

Zhitong FinanceMay 29 17:43

Oriental Securities: Breakthroughs Across Multiple Segments in the Pharmaceutical Sector Drive Rising Global Influence of Domestic Innovation

Domestically developed innovative drugs are characterized by the concurrent advancement of multiple mechanisms and numerous specific indications, holding promise as new treatment options and potentially reshaping current therapeutic paradigms.

Zhitong FinanceMay 27 10:38

Huahai Pharmaceutical (600521): Integrated API and Formulation Business; Innovative Drugs Poised for Growth

Huahai Pharmaceutical: Global footprint with coordinated development across active pharmaceutical ingredients (APIs), generics, and innovative drugs. With over three decades of expertise in pharmaceutical manufacturing, Huahai has established an integrated 'intermediate–API–finished dosage form' business model and expanded into biologics and innovative drug development. The company is actively advancing

Changjiang SecuritiesMay 27 07:42